Capecitabine and oxaliplatin for advanced esophagogastric cancer

David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom

doi:10.1056/NEJMoa073149

Capecitabine and oxaliplatin for advanced esophagogastric cancer

David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, Marianne Nicolson, Fareeda Coxon, Gary Middleton, Francis Daniel, Jacqueline Oates, Andrew Richard Norman, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom

Research output: Contribution to journal › Article › peer-review

1671 Citations (Scopus)

Abstract

We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer.

Original language	English
Pages (from-to)	36-46
Number of pages	11
Journal	The New England Journal of Medicine
Volume	358
Issue number	1
DOIs	https://doi.org/10.1056/NEJMoa073149
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMoa073149

Cite this

Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., Norman, A. R., & Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England Journal of Medicine, 358(1), 36-46. https://doi.org/10.1056/NEJMoa073149

@article{2cefdb41acc449f8b41630d7bf39cc0d,

title = "Capecitabine and oxaliplatin for advanced esophagogastric cancer",

abstract = "We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer.",

author = "David Cunningham and Naureen Starling and Sheela Rao and Timothy Iveson and Marianne Nicolson and Fareeda Coxon and Gary Middleton and Francis Daniel and Jacqueline Oates and Norman, {Andrew Richard} and {Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom}",

year = "2008",

doi = "10.1056/NEJMoa073149",

language = "English",

volume = "358",

pages = "36--46",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "1",

}

Cunningham, D, Starling, N, Rao, S, Iveson, T, Nicolson, M, Coxon, F, Middleton, G, Daniel, F, Oates, J, Norman, AR & Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom 2008, 'Capecitabine and oxaliplatin for advanced esophagogastric cancer', The New England Journal of Medicine, vol. 358, no. 1, pp. 36-46. https://doi.org/10.1056/NEJMoa073149

TY - JOUR

T1 - Capecitabine and oxaliplatin for advanced esophagogastric cancer

AU - Cunningham, David

AU - Starling, Naureen

AU - Rao, Sheela

AU - Iveson, Timothy

AU - Nicolson, Marianne

AU - Coxon, Fareeda

AU - Middleton, Gary

AU - Daniel, Francis

AU - Oates, Jacqueline

AU - Norman, Andrew Richard

AU - Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom

PY - 2008

Y1 - 2008

N2 - We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer.

AB - We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer.

U2 - 10.1056/NEJMoa073149

DO - 10.1056/NEJMoa073149

M3 - Article

C2 - 18172173

SN - 0028-4793

VL - 358

SP - 36

EP - 46

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 1

ER -

Capecitabine and oxaliplatin for advanced esophagogastric cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this